Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Isofol Medical AB ( (SE:ISOFOL) ) has issued an announcement.
Isofol Medical AB will participate in the ASCO GI Cancer Symposium in San Francisco, where it will present a Trial in Progress abstract outlining the design and recruitment status of its ongoing phase Ib/II study of arfolitixorin in metastatic colorectal cancer. The study, conducted at Charité – Universitätsmedizin Berlin, tests a new dosing regimen and escalating doses of arfolitixorin in combination with 5-FU chemotherapy, oxaliplatin and bevacizumab as first-line treatment, underscoring the candidate’s potential to address a significant treatment gap in one of the world’s most common and deadly cancers. Company executives describe the congress appearance and planned advisory-board meetings as an important start to the year, as Isofol aims to complete the first part of the trial and move into phase II, a step that could prove pivotal for its clinical development program and its positioning in colorectal cancer therapeutics.
The most recent analyst rating on (SE:ISOFOL) stock is a Hold with a SEK0.69 price target. To see the full list of analyst forecasts on Isofol Medical AB stock, see the SE:ISOFOL Stock Forecast page.
More about Isofol Medical AB
Isofol Medical AB is a Swedish biopharmaceutical company focused on improving outcomes and quality of life for patients with severe forms of cancer. Its lead clinical-stage drug candidate, arfolitixorin, is designed to enhance the effect of first-line standard treatments for solid tumors and is currently being evaluated in colorectal cancer, where there is a pronounced unmet medical need. The company is listed on Nasdaq Stockholm and is conducting a phase Ib/II study with an optimized dosing regimen intended to maximize the drug’s therapeutic impact.
Average Trading Volume: 465,538
Technical Sentiment Signal: Strong Sell
Current Market Cap: SEK205.5M
For a thorough assessment of ISOFOL stock, go to TipRanks’ Stock Analysis page.